Opioid treatment in pregnancy: which form is safer for Baby's brain?
NCT ID NCT03911739
First seen Mar 22, 2026 · Last updated Jun 21, 2026 · Updated 16 times
Summary
This study followed 71 infants whose mothers took either a monthly injection or a daily tablet of buprenorphine for opioid use disorder during pregnancy. Researchers used the Bayley Scales of Infant Development to measure cognitive, language, and motor skills. The goal is to see if the extended-release injection leads to better infant neurodevelopment than the daily tablet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Addiction Recovery Services (ARS), Swedish Medical Center
Seattle, Washington, 98107, United States
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
CODA, Inc.
Portland, Oregon, 97214, United States
-
Gateway Community Services
Jacksonville, Florida, 32204, United States
-
Marshall Health MARC Program
Huntington, West Virginia, 25701, United States
-
Massachusetts General Hospital HOPE Clinic
Boston, Massachusetts, 02114, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Pregnancy Recovery Center at Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
-
University of Utah SUPeRAD Clinic
Salt Lake City, Utah, 84108, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
buprenorphine (extended-release injection vs. daily sublingual tablet)
What this could lead to
If it works, this could help doctors choose the safest form of buprenorphine for pregnant women to protect infant brain development.
What could go wrong
This is a small, completed sub-study (71 infants) that only observes outcomes, not a large trial testing a new treatment. Results may not apply to all populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.